Inspire Pharmaceuticals Revenue and Competitors
Estimated Revenue & Valuation
- Inspire Pharmaceuticals's estimated annual revenue is currently $125.4M per year.
- Inspire Pharmaceuticals's estimated revenue per employee is $201,000
Employee Data
- Inspire Pharmaceuticals has 624 Employees.
- Inspire Pharmaceuticals grew their employee count by 35% last year.
Inspire Pharmaceuticals's People
Name | Title | Email/Phone |
---|
Inspire Pharmaceuticals Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $46.2M | 230 | 5% | N/A | N/A |
#2 | $43.8M | 218 | 21% | N/A | N/A |
#3 | $57.1M | 284 | 26% | N/A | N/A |
#4 | $24.5M | 122 | 3% | N/A | N/A |
#5 | $52.9M | 263 | 13% | N/A | N/A |
#6 | $24.7M | 123 | 13% | N/A | N/A |
#7 | $1.8M | 18 | 0% | $114.3M | N/A |
#8 | $7.2M | 36 | -20% | N/A | N/A |
#9 | $13.7M | 68 | -7% | N/A | N/A |
#10 | $7.6M | 39 | -13% | $123.9M | N/A |
What Is Inspire Pharmaceuticals?
Inspire is a biopharmaceutical company focused on researching, developing and commercializing prescription pharmaceutical products for ophthalmic and pulmonary diseases. Inspire's goal is to build and commercialize a sustainable portfolio of innovative new products based on its technical, scientific and commercial expertise. The most advanced compounds in Inspire's clinical pipeline are denufosol tetrasodium for cystic fibrosis and PROLACRIA(TM) (diquafosol tetrasodium ophthalmic solution) 2% for dry eye, which are both in Phase 3 development, and AZASITE(R) (azithromycin ophthalmic solution) 1% for blepharitis, which is in Phase 2 development. Inspire receives revenues related to the promotion of AZASITE for bacterial conjunctivitis, the co-promotion of ELESTAT(R) (epinastine HCl ophthalmic solution) 0.05% for allergic conjunctivitis and royalties based on net sales of RESTASIS(R) (cyclosporine ophthalmic emulsion) 0.05% for dry eye.
keywords:N/AN/A
Total Funding
624
Number of Employees
$125.4M
Revenue (est)
35%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Inspire Pharmaceuticals News
The pharma industry is still holding on to its COVID-19 halo in the eyes of ... BioMarin is looking to help inspire the next generation of...
BioMarin joins pharma's filmmaking push with hemophilia documentary project ... BioMarin is looking to help inspire the next generation of filmmakers while...
Forrest Xu, a partner at Virtus Inspire Ventures commented: We recognize the great potential of Design Pharmaceuticals' platform to...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $3.5M | 624 | 33% | N/A |
#2 | $137.9M | 625 | 2% | N/A |
#3 | $117.2M | 625 | 0% | N/A |
#4 | $117.2M | 625 | 35% | N/A |
#5 | N/A | 625 | 8% | N/A |